This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.
—We read with interest the report by Drs. Tabbara, Nozik, and O'Connor in the Archives (92:244-247, 1974) on the efficacy of clindamycin in the treatment of experimentally induced ocular toxoplasmosis. The search for a less toxic means of treating ocular toxoplasmosis is indeed important. With respect to the possible ocular toxicity of clindamycin in patients, our experience at the Retinal Service of the New York Hospital with clindamycin as a prophylactic agent to prevent infections resulting from a scleral buckling procedure may be of value.For the past year, it has been our practice to soak our silicone sponge explants in clindamycin prior to their placement. In addition, 0.75 ml of clindamycin (150 mg/ml) is injected below the Tenon capsule at the conclusion of the procedure. During the period in which we have been using clindamycin, we have noted no adverse effects.
Parver L, Lincoff H. Clindamycin and Toxoplasmosis. Arch Ophthalmol. 1975;93(7):546. doi:10.1001/archopht.1975.01010020562030
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: